PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities. Looking for a new role? Please visit our careers page to find out more about our open jobs and benefits at https://phasebio.com/careers/
View Top Employees from PhaseBio Pharmaceuticals, Inc.| Website | http://www.phasebio.com |
| Ticker | PHAS |
| Revenue | $10.9 million |
| Funding | $389.2 million |
| Employees | 39 (39 on RocketReach) |
| Founded | 2002 |
| Address | 1 Great Valley Parkway Suite 30, Malvern, Pennsylvania 19355, US |
| Phone | (610) 981-6500 |
| Fax | (610) 981-6520 |
| Technologies |
JavaScript,
HTML,
PHP
+41 more
(view full list)
|
| Industry | Biotechnology, Pharmaceuticals, Drug Delivery, Healthcare, Science and Engineering, Medical, Health Care, Medical Device, Pharmaceutical |
| Web Rank | 6 Million |
| Keywords | Phasebio, Phasebio Pharmaceuticals Inc, Pb2452 Injection, Phase Bio, Phasebio Pharmaceuticals |
| Competitors | Bellerophon Therapeutics, CymaBay Therapeutics, Lyndra Therapeutics, Madrigal Pharmaceuticals, Visterra Inc. |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular PhaseBio Pharmaceuticals, Inc. employee's phone or email?
PhaseBio Pharmaceuticals, Inc. Questions
The PhaseBio Pharmaceuticals, Inc. annual revenue was $10.9 million in 2024.
John Lee is the Chief Medical Officer of PhaseBio Pharmaceuticals, Inc..
39 people are employed at PhaseBio Pharmaceuticals, Inc..
PhaseBio Pharmaceuticals, Inc. is based in Malvern, Pennsylvania.
The NAICS codes for PhaseBio Pharmaceuticals, Inc. are [3254, 325, 32541, 32].
The SIC codes for PhaseBio Pharmaceuticals, Inc. are [28, 283].
Top PhaseBio Pharmaceuticals, Inc. Employees
-
42
-
21
-
5+4
-
View
Susan Maloney-Kopf
AVP and Head Clinical Operations at PhaseBio Pharmaceuticals, Inc.
Conshohocken, PA, US24 -
ViewTasha Hutchinson
Sr. Manager, CMC Quality Assurance at PhaseBio Pharmaceuticals, Inc.
Nescopeck, PA, US33 -
31
Related Companies
